Search / 192 results found

  • Updated

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 /PRNewswire/ -- Verinetics has been awarded a $1.5 million contract the National Institutes of Health's National Institute on Drug Abuse (NIDA) under the Small Business Innovation Research Program (SBIR) Phase II program. Verinetics will use the award to develop a system called DispenSecur version 1 (DSv1), objectives of which are to expand access to medications to treat opioid use disorder (MOUD).

More Americans are dying from drug overdoses than ever before, according to the Centers for Disease Control and Prevention. There were an estimated 100,306 fatal overdoses over the 12 months through April 2021 — the most ever reported in a 12-month period and double the annual number of car accidents and firearm deaths combined. The […]

  • Updated

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2021 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH), being held from December 11- 14, 2021, virtually and in-person in Atlanta. Dr. Adrian Schwarzer, MD, PhD, Hannover Medical School, will present non-clinical research on the activity and mechanism of BTM-3566 a novel, oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis.